SOURCE: Tiziana Life Sciences PLC

August 18, 2016 02:00 ET

Tiziana Life Sciences PLC: Change of Registered Office

LONDON, UNITED KINGDOM--(Marketwired - Aug 18, 2016) - Tiziana Life Sciences plc (AIM: TILS)

AIM: TILS

Tiziana Life Sciences PLC

("Tiziana" or the "Company")

Change in Registered Office

London, 18 August 2016 - Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, today announces that its registered office address has changed to: 3rd Floor 11-12 St. James's Square, London, United Kingdom, SW1Y 4LB.

 
Contacts:
 
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder
  +44 (0)20 7493 2853
     
Cairn Financial Advisers LLP (Nominated adviser)
Liam Murray
  +44 (0)20 7148 7900
     
Beaufort Securities Limited (Broker)
Saif Janjua
  +44 (0)20 7382 8300
     
FTI Consulting
Simon Conway / Rob Winder / Natalie Garland-Collins
  +44 (0)20 3727 1000
     

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology.

The Company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently completing phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy and has filed an IND to enroll patients in an exploratory trial in Hepatic Cellular Carcinoma (HCC).

The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

Tiziana Life Sciences' clinical development teams are working on its Bcl-3 candidate; which has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be a regulator of cancer cell motility and has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in aggressive breast cancers, but across the clinical spectrum of breast disease. The Company is preparing the IND package with the intention of progressing to clinical trials early 2017.

For more information go to http://www.tizianalifesciences.com

Contact Information